National and Kapodistrian University of Athens
Αναγνώριση των ενεργοποιημένων κινασών τυροσίνης και άλλων σημείων των οδών μεταγωγής σήματος με χημικούς παράγοντες που μπορούν να μετέχουν στη δημιουργία χρόνιων μυεολοϋπερπλαστικών συνδρόμων (ΧΜΥΣ)
Abstract
dc:descriptionMyeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders resulting from the transformation of a hematopoietic stem cell (HSC), with abnormal amplification of one or several myeloid lineages. The classic MPNs comprise chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Less frequent MPNs are chronic eosinophilic leukemia (CEL), hypereosinophilic syndrome (HES), chronic neutrophilic leukemia (CNL), chronic baseophilic leukemia (CBL), systemic mastocytosis (SM), and other unclassifiable MPNs. Pathogenesis of most MPNs involve the deregulation of a tyrosine kinase that mimics the physiological intracellular signaling pathways induced by hematopoietic cytokine receptors. Pathogenetic breakthroughs in MPN began in decade 1980 when fusion gene BCR-ABL were describe in CML where as the next decades were found many other fusion genew and point mutations that were related with the respective phenotype in MPN. JAK2V617F was the most important point mutation that was described in patients with PV, ET and PMF. The present thesis was focused in study of HES, which is a rare and heterogeneous group of disorders, and characterized by the following criteria according to WHO: (i) persistent blood eosinophilia >1500/μL for more than six months, (ii) exclusion of any secondary causes of eosinophilia such as allergy, parasitic infections, autoimmune diseases and cancer, and (iii) eosinophil organ damage, mainly skin, heart, lungs and nervous system. For this reason 160 samples of peripheral blood were collected from patients who fulfilled the above diagnostic criteria, and were examined for the JAK2V617F and CKITD816V point mutations and for the BCR-ABL, FIP1L1-PDGFRA, BCR-PDGFRB, ETV6-PDGFRB, BCR-FGFR1, ZNF198-FGFR1, CEP110-FGFR1 and FOP-FGFR1 fusion genes. 7 patients with mild eosinophilia were described to be positive for the JAK2V617F, 3 patients with mild eosinophilia were described to be positive for the CKITD816V where as in 4 patients with slightly leukocytosis and eosinophilia were described to be positive for FIP1L1-PDGFRA. The fusion genes BCR-ABL, BCR-PDGFRB, ETV6-PDGFRB, BCR-FGFR1, ZNF198-FGFR1, CEP110-FGFR1 and FOP-FGFR1 weren’t found in any patient. Patients who carry the fusion gene FIP1L1-PDGFRA followed a treatment with imatinib mesylate and had hematological, clinical and molecular remission within one month. Furthermore, 4 patients HES and 2 CEL followed a treatment with dasatinib because of unsuccessful treatment with corticosteroid, imatinib and hydroxyouria. 4 patients had hematological and clinical remission within two months. The molecular mechanisms that cause significantly increased eosinophil count are unknown. As a result patients have high mortality risk because of the accumulation of eosinophils in tissues. For these reasons, it is quite important to discover new molecular markers as therapeutic targets in HES. Proteomics is a useful technique that can provide a global description and identification of the proteins expressed in a cell at a certain time. Many genes can be activated or silenced in neoplasmatic states so there will be differences in protein expression levels. Such differences can be detected in 2-Dimentional Gel Electrophoresis. In the present study, we used a global proteomic approach by 2-Dimentional Gel Electrophoresis to identify the modification of proteome induced by F/P fusion gene in EOL-1 cell line comparing with the proteome of leukemic cell lines K562 (express BCR-ABL fusion gene), CCRF-CEM and HEL. Furthermore, the same approach was used to detect differences between the proteome of circulated monocytes from healthy volunteers and CEL patients (presence of F/P fusion gene), HES patients and CML patients. We show several differences in protein expression levels between the proteome of EOL-1 and K562, CCRF-CEM and HEL and identified 51, 35 and 35 proteins respectively. These proteins have different molecular functions such as structural proteins of cytoskeleton, metabolic enzymes and signal transducers. Followed the same approach, we analyze the proteome of circulated monocytes from 2 patients with eosinophilia that express F/P fusion gene, from 4 patients with unexplained eosinophilia (HES), from 4 patients that express BCR-ABL fusion gene (CML) and from 10 healthy volunteers. We compare the proteome between healthy volunteers and F/P patients, healthy volunteers and HES patients, HES patients and F/P patients, and HES patients with CML patients and emerge 34, 30 and 10 proteins with different expression levels. To conclude, HES is a rare hematologic disorder where pathological causes and molecular functions are unknown. Proteomic analysis provides the opportunity to investigate such molecular mechanisms, since it gives global information of genes that is being expressed by a cell in an abnormal or diseased state. So, proteins that were being identified and had different expression levels between healthy and diseased cells, might be used as disease markers or candidates for therapeutic intervention.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gota, Vaia
- Γώτα, Βαΐα
Subjects
dc:subject × 14- Χρόνια μυελοϋπερπλαστικά σύνδρομα ΧΜΥΣ
- Υπερηωσινοφιλικό σύνδρομο
- Χρόνια ηωσινοφιλική λευχαιμία
- Μεταγωγή σήματος
- Πρωτεωμική ανάλυση
- Chronic myeloproliferative disorders
- Hypereosinophilic syndrome
- Chronic eosinophilic leukemia
- Signal transduction
- Proteomic analysis
- Ιατρική και Επιστήμες Υγείας
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27879